Eleven Biotherapeutics Inc. (EBIO) Director Abbie Celniker Sells 10,031 Shares
Eleven Biotherapeutics Inc. (NASDAQ:EBIO) Director Abbie Celniker sold 10,031 shares of the company’s stock in a transaction that occurred on Wednesday, September 28th. The shares were sold at an average price of $3.00, for a total value of $30,093.00. Following the sale, the director now owns 409,915 shares in the company, valued at approximately $1,229,745. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Shares of Eleven Biotherapeutics Inc. (NASDAQ:EBIO) opened at 2.80 on Friday. Eleven Biotherapeutics Inc. has a 52 week low of $0.25 and a 52 week high of $5.97. The firm’s market cap is $43.10 million. The firm’s 50-day moving average price is $4.23 and its 200 day moving average price is $2.31.
Eleven Biotherapeutics (NASDAQ:EBIO) last announced its quarterly earnings results on Friday, August 12th. The biopharmaceutical company reported ($0.33) earnings per share (EPS) for the quarter. Eleven Biotherapeutics had a negative net margin of 2,995.34% and a negative return on equity of 207.40%. Equities analysts anticipate that Eleven Biotherapeutics Inc. will post ($1.75) EPS for the current year.
Several institutional investors have recently made changes to their positions in EBIO. Boxer Capital LLC purchased a new position in shares of Eleven Biotherapeutics during the second quarter valued at about $1,670,000. Flagship Ventures Fund IV General Partner LLC bought a new position in shares of Eleven Biotherapeutics during the second quarter worth $2,464,000. Bank of New York Mellon Corp raised its position in shares of Eleven Biotherapeutics by 13.2% in the second quarter. Bank of New York Mellon Corp now owns 67,483 shares of the biopharmaceutical company’s stock worth $112,000 after buying an additional 7,846 shares during the last quarter. Flagship Ventures Fund IV L.P. bought a new position in shares of Eleven Biotherapeutics during the first quarter worth $469,000. Finally, Flagship Ventures Fund 2007 L.P. bought a new position in shares of Eleven Biotherapeutics during the first quarter worth $610,000. 34.32% of the stock is owned by institutional investors.
About Eleven Biotherapeutics
Eleven Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company through AMP-Rx, a protein engineering platform, is engaged in the discovery and development of protein therapeutics to treat diseases of the eye. The Company designs, engineers and generates a pipeline of protein therapeutic candidates that target cytokines, which are central to diseases of the eye.
Receive News & Stock Ratings for Eleven Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eleven Biotherapeutics Inc. and related stocks with our FREE daily email newsletter.